Drug Discovery: Genomic and Transcriptomic Approaches
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 3258
Special Issue Editor
Special Issue Information
Dear Colleagues,
With the development of sequencing capability and bioinformatics analytic tools, omics have become an indispensable tool in modern drug discovery. High-throughput data such as genomic, epigenetic, transcriptomic, proteomic, metabolomic, and ribosome profiling data as well as single-cell sequencing have all made significant contributions to mechanism-based drug discovery and drug repurposing. Omics data analysis can not only accelerate drug target identification and drug candidate screening but can also facilitate the characterization of side effects and predict drug resistance.
For this Special Issue, we encourage the use of omics data for drug-discovery-related exploration, aiming to provide a forum for advances in the development and application of omics-based drug-discovery strategies.
Original research articles and reviews that focus on, but are not limited to, the following topics are welcome:
- The identification or verification of drug targets and biomarkers by integrating diverse omics data;
- The identification of disease-associated screenable phenotypes based on omics data analysis;
- The prediction or refinement of drug candidates through omics data mining;
- Assessment of the potential for drug resistance or adverse drug reactions using omics data;
- Prediction of a drug's activity, toxicity, or mechanism of action through omics data analysis.
Prof. Dr. Keshen Li
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- omics
- bioinformatics
- drug discovery
- drug response
- drug target
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
